Bone health in children undergoing solid organ transplantation.
Journal
Current opinion in pediatrics
ISSN: 1531-698X
Titre abrégé: Curr Opin Pediatr
Pays: United States
ID NLM: 9000850
Informations de publication
Date de publication:
01 12 2023
01 12 2023
Historique:
medline:
2
11
2023
pubmed:
9
10
2023
entrez:
9
10
2023
Statut:
ppublish
Résumé
Pediatric solid organ transplant recipients are a unique and growing patient population who are at risk for metabolic bone disease both before and after transplantation. The odds of sustaining a fracture in adulthood are significantly higher if an individual has sustained at least one childhood fracture, therefore, close monitoring before and after transplant is essential. Emerging data in patients with chronic kidney disease mineral and bone disorder (CKD-MBD) and hepatic osteodystrophy highlights the role of fibroblast growth factor 23 in the pathogenesis of metabolic bone disease in these conditions. While dual X-ray absorptiometry (DXA) is the most widely used imaging modality for assessment of bone mass in children, quantitative computer tomography (QCT) is an emerging modality, especially for patients with glucocorticoid-induced osteoporosis. Solid organ transplantation improves organ function and quality of life; however, bone mineral density can decline following transplantation, particularly during the first three to six months. Immunosuppressive medications, including glucocorticoids, are a major contributing factor. Following transplant, treatment should be tailored to achieve mineral homeostasis, correct nutritional deficiencies, and improve physical conditioning. In summary, early identification and treatment of metabolic bone disease can improve the bone health status of pediatric transplant recipients as they enter adulthood. http://links.lww.com/MOP/A71.
Identifiants
pubmed: 37811914
doi: 10.1097/MOP.0000000000001290
pii: 00008480-990000000-00130
doi:
Substances chimiques
Glucocorticoids
0
Types de publication
Review
Video-Audio Media
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
703-709Informations de copyright
Copyright © 2023 Wolters Kluwer Health, Inc. All rights reserved.
Références
https://unos.org/data/ .
Florencio-Silva R, Sasso GR, Sasso-Cerri E, et al. Biology of bone tissue: structure, function, and factors that influence bone cells. Biomed Res Int 2015; 2015:421746.
Bonewald LF. The amazing osteocyte. J Bone Miner Res 2011; 26:229–238.
Ott SM. Cortical or trabecular bone: what's the difference? Am J Nephrol 2018; 47:373–375.
Boot AM, de Ridder MA, van der Sluis IM, et al. Peak bone mineral density, lean body mass and fractures. Bone 2010; 46:336–341.
Kim MJ, Jillian H, Rachael T, et al. Is repeated childhood fracture related to areal bone density or body composition in middle age? Osteoporos Int 2022; 33:2369–2379.
Hu L, Napoletano A, Provenzano M, et al. Mineral bone disorders in kidney disease patients: the ever-current topic. Int J Mol Sci 2022; 23:
Portale AA, Wolf M, Jüppner H, et al. Disordered FGF-23 and mineral metabolism in children with CKD. Clin J Am Soc Nephrol 2014; 9:344–353.
López-Larramona G, Lucendo AJ, González-Castillo S, Tenias JM. Hepatic osteodystrophy: an important matter for consideration in chronic liver disease. World J Hepatol 2011; 3:300–307.
Kelly DA, Bucuvalas JC, Alonso EM, et al. Long-term medical management of the pediatric patient after liver transplantation: 2013 practice guideline by the American Association for the Study of Liver Diseases and the American Society of Transplantation. Liver Transpl 2013; 19:798–825.
Yuksel M, Demir B, Mizikoğlu Ö, et al. Course of vitamin D levels before and after liver transplantation in pediatric patients. Pediatr Transplant 2021; 25:e14049.
Yang YJ, Kim DJ. An overview of the molecular mechanisms contributing to musculoskeletal disorders in chronic liver disease: osteoporosis, sarcopenia, and osteoporotic sarcopenia. Int J Mol Sci 2021; 22:
Ng NBH, Karthik SV, Lee YS, Aw MM. Hepatic osteodystrophy with hypophosphataemia and elevated fibroblast growth factor-23. J Paediatr Child Health 2022; 58:1864–1867.
van der Burgh AC, Oliai Araghi S, Zillikens MC, et al. The impact of thiazide diuretics on bone mineral density and the trabecular bone score: the Rotterdam Study. Bone 2020; 138:115475.
Barnes C, Newall F, Ignjatovic V, et al. Reduced bone density in children on long-term warfarin. Pediatr Res 2005; 57:578–581.
Sandberg C, Johansson K, Christersson C, et al. Low bone mineral density in adults with complex congenital heart disease. Int J Cardiol 2020; 319:62–66.
Signorelli SS, Scuto S, Marino E, et al. Anticoagulants and osteoporosis. Int J Mol Sci 2019; 20:
Gatti S, Quattrini S, Palpacelli A, et al. Metabolic bone disease in children with intestinal failure and long-term parenteral nutrition: a systematic review. Nutrients 2022; 14:
Ramsey-Goldman R, Dunn JE, Dunlop DD, et al. Increased risk of fracture in patients receiving solid organ transplants. J Bone Miner Res 1999; 14:456–463.
Cayco AV, Wysolmerski J, Simpson C, et al. Posttransplant bone disease: evidence for a high bone resorption state. Transplantation 2000; 70:1722–1728.
Guichelaar MM, Kendall R, Malinchoc M, Hay JE. Bone mineral density before and after OLT: long-term follow-up and predictive factors. Liver Transpl 2006; 12:1390–1402.
Helenius I, Remes V, Salminen S, et al. Incidence and predictors of fractures in children after solid organ transplantation: a 5-year prospective, population-based study. J Bone Miner Res 2006; 21:380–387.
Anastasilakis AD, Tsourdi E, Makras P, et al. Bone disease following solid organ transplantation: a narrative review and recommendations for management from the European Calcified Tissue Society. Bone 2019; 127:401–418.
Halton J, Gaboury I, Grant R, et al. Advanced vertebral fracture among newly diagnosed children with acute lymphoblastic leukemia: results of the Canadian Steroid-Associated Osteoporosis in the Pediatric Population (STOPP) research program. J Bone Miner Res 2009; 24:1326–1334.
Schreiber SL, Crabtree GR. The mechanism of action of cyclosporin A and FK506. Immunol Today 1992; 13:136–142.
Kanda J, Izumo N, Furukawa M, et al. Effects of the calcineurin inhibitors cyclosporine and tacrolimus on bone metabolism in rats. Biomed Res 2018; 39:131–139.
Pereira RC, Valta H, Tumber N, et al. Altered osteocyte-specific protein expression in bone after childhood solid organ transplantation. PLoS One 2015; 10:e0138156.
Mogi M, Kondo A. Down-regulation of mTOR leads to up-regulation of osteoprotegerin in bone marrow cells. Biochem Biophys Res Commun 2009; 384:82–86.
Kneissel M, Luong-Nguyen NH, Baptist M, et al. Everolimus suppresses cancellous bone loss, bone resorption, and cathepsin K expression by osteoclasts. Bone 2004; 35:1144–1156.
Chen J, Tu X, Esen E, et al. WNT7B promotes bone formation in part through mTORC1. PLoS Genet 2014; 10:e1004145.
Kim JM, Yang YS, Hong J, et al. Biphasic regulation of osteoblast development via the ERK MAPK-mTOR pathway. Elife 2022; 11:e78069.
Shuhart CR, Yeap SS, Anderson PA, et al. Executive summary of the 2019 ISCD position development conference on monitoring treatment, DXA cross-calibration and least significant change, spinal cord injury, peri-prosthetic and orthopedic bone health, transgender medicine, and pediatrics. J Clin Densitom 2019; 22:453–471.
Gonera-Furman A, Bolanowski M, Jędrzejuk D. Osteosarcopenia—the role of dual-energy X-ray absorptiometry (DXA) in diagnostics. J Clin Med 2022; 11:2522.
Bishop N, Arundel P, Clark E, et al. Fracture prediction and the definition of osteoporosis in children and adolescents: the ISCD 2013 Pediatric Official Positions. J Clin Densitom 2014; 17:275–280.
Wasserman H, O’Donnell JM, Gordon CM. Use of dual energy X-ray absorptiometry in pediatric patients. Bone 2017; 104:84–90.
Karava V, Printza N. Reconsidering DXA usefulness for the evaluation of bone disorders in children with chronic kidney disease. Pediatr Nephrol 2022; 37:2799–2800.
Link TM, Kazakia G. Update on imaging-based measurement of bone mineral density and quality. Curr Rheumatol Rep 2020; 22:13.
Tezol O, Balci Y, Alakaya M, et al. Bone densitometry measurements in children with neurofibromatosis Type 1 using quantitative computed tomography. Singapore Med J 2022; 63:520–526.
Liu C, Yang DD, Zhang L, et al. Bone mineral density assessment by quantitative computed tomography in glucocorticoid-treated boys with duchenne muscular dystrophy: a linear mixed-effects modeling approach. Front Endocrinol (Lausanne) 2022; 13:860413.
Lee JS, Kim K, Jeon YK, et al. Effects of traction on interpretation of lumbar bone mineral density in patients with duchenne muscular dystrophy: a new measurement method and diagnostic criteria based on comparison of dual-energy X-ray absorptiometry and quantitative computed tomography. J Clin Densitom 2020; 23:53–62.
Jaworski M, Kobylińska M, Graff K. Peripheral quantitative computed tomography of the lower leg in children and adolescents: bone densities, cross-sectional sizes and muscle distribution reference data. J Musculoskelet Neuronal Interact 2021; 21:215–236.
Roggen I, Roelants M, Sioen I, et al. Pediatric reference values for tibial trabecular bone mineral density and bone geometry parameters using peripheral quantitative computed tomography. Calcif Tissue Int 2015; 96:527–533.
Lalayiannis AD, Fewtrell M, Biassoni L, et al. Studying bone mineral density in young people: The complexity of choosing a pQCT reference database. Bone 2021; 143:115713.
Stein EM, Ortiz D, Jin Z, et al. Prevention of fractures after solid organ transplantation: a meta-analysis. J Clin Endocrinol Metab 2011; 96:3457–3465.
Brunova J, Kratochvilova S, Stepankova J. Osteoporosis therapy with denosumab in organ transplant recipients. Front Endocrinol (Lausanne) 2018; 9:162.
Boyce AM. Denosumab: an emerging therapy in pediatric bone disorders. Curr Osteoporos Rep 2017; 15:283–292.
Janaudis-Ferreira T, Tansey CM, Mathur S, et al. The effects of exercise training in adult solid organ transplant recipients: a systematic review and meta-analysis. Transpl Int 2021; 34:801–824.